UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 942

Sortiert nach

Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients

Osteoarthritis and cartilage, 2005-05, Vol.13 (5), p.361-367

2005

Link zum Volltext

Verfügbarkeit prüfen

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis

Scandinavian journal of rheumatology, 2017-09, Vol.46 (5), p.396-406

2017

Link zum Volltext

Verfügbarkeit prüfen

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA)

Clinical rheumatology, 2020-01, Vol.39 (1), p.189-199

2020

Link zum Volltext

Verfügbarkeit prüfen

Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait‐Listed and Transplanted Renal Allograft Recipients

American journal of transplantation, 2003-05, Vol.3 (5), p.590-598

2003

Link zum Volltext

Verfügbarkeit prüfen

AB0745 Assessing validity of low field magnetic resonance imaging (mri) for joint inflammation and damage in wrist/hand rheumatoid arthritis (ra) - a systematic literature review (slr)

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A1016-A1017

2013

Link zum Volltext

Verfügbarkeit prüfen

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies

Journal of rheumatology, 2001-05, Vol.28 (5), p.1163

2001

Link zum Volltext

Verfügbarkeit prüfen

Response of psoriasis to a lymphocyte-selective toxin (DAB sub(389)IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Nature medicine, 1995-05, Vol.1 (5), p.442-447

1995

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of an interleukin‐2 fusion toxin (DAB486IL‐2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy

Cancer, 1994-02, Vol.73 (4), p.1276-1285

1994

Link zum Volltext

Verfügbarkeit prüfen

Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus

Clinical and experimental rheumatology, 1993-03, Vol.11 Suppl 8, p.S177

Woodworth, T G

1993

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes

The Journal of immunology (1950), 2000-03, Vol.164 (6), p.3392-3401

2000

Link zum Volltext

Verfügbarkeit prüfen

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Arthritis research & therapy, 2008-01, Vol.10 (3), p.R67-R67

2008

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis

Atherosclerosis, 1996-09, Vol.126 (1), p.1-14

1996

Link zum Volltext

Verfügbarkeit prüfen

Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Nature medicine, 1995-05, Vol.1 (5), p.442-447

1995

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-2 Receptor-Directed Therapies: Antibody-or Cytokine-Based Targeting Molecules

Annual review of medicine, 1993, Vol.44 (1), p.343-353

1993

Link zum Volltext

Verfügbarkeit prüfen

MRI assessment of knee osteoarthritis: Knee Osteoarthritis Scoring System (KOSS): inter-observer and intra-observer reproducibility of a compartment-based scoring system

Skeletal radiology, 2005-02, Vol.34 (2), p.95-102

2005

Link zum Volltext

Verfügbarkeit prüfen

AB1182 Cognitive Debrief of the English Version of the French Flare Assessment in Rheumatoid Arthritis (FLARE) Questionnaire in American English-Speaking RA Patients

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1298-1298

2015

Link zum Volltext

Verfügbarkeit prüfen

FRI0203 Sustained Drug Free Remission in Early Ra Patients Treated To Target with Tocilizumab, Methotrexate or Their Combination

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.504-505

2016

Link zum Volltext

Verfügbarkeit prüfen

FRI0040 Protein Biomarkers Improves The Prediction of Clinical Response To Methotrexate Step-Up Strategy in Early RA Patients

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.440-440

2016

Link zum Volltext

Verfügbarkeit prüfen

Recombinant fusion toxins--a new class of targeted biologic therapeutics

Cancer treatment and research, 1993, Vol.68, p.145

1993

Link zum Volltext

Verfügbarkeit prüfen

OP0033 Rapid and Sustained Remission in Early Rheumatoid Arthritis (RA) Treated to Target with Tocilizumab, Methotrexate, or their Combination: The U-Act-Early Strategy Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.77-78

2015

Link zum Volltext

Verfügbarkeit prüfen

OP0250 Exploration of omeract preliminary rheumatoid arthritis (RA) flare domains in a longitudinal observational study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.140-140

2013

Link zum Volltext

Verfügbarkeit prüfen

SAT0218 Validating Responsiveness and Discrimination of the Rheumatoid Arthritis Magnetic Resonance Imaging SCORE (RAMRIS) – A Meta-Analysis of Randomized Controlled Trials (RCTS) Identified in A Systematic Literature Review

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.669

2014

Link zum Volltext

Verfügbarkeit prüfen

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update

Journal of rheumatology, 2005-10, Vol.32 (10), p.2037

2005

Link zum Volltext

Verfügbarkeit prüfen

Interleukin‐2 diphtheria fusion protein (dab486il‐2) in refractory rheumatoid arthritis a double‐blind, placebo‐controlled trial with open‐label extension

Arthritis and rheumatism, 1995-09, Vol.38 (9), p.1177-1186

1995

Link zum Volltext

Verfügbarkeit prüfen

Challenges and progress in adverse event ascertainment and reporting in clinical trials

Journal of rheumatology, 2005-10, Vol.32 (10), p.2030

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 942

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(761)
Mit Volltextzugriff
(821)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA)

Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait‐Listed and Transplanted Renal Allograft Recipients

AB0745 Assessing validity of low field magnetic resonance imaging (mri) for joint inflammation and damage in wrist/hand rheumatoid arthritis (ra) - a systematic literature review (slr)

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies

Response of psoriasis to a lymphocyte-selective toxin (DAB sub(389)IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Phase I trial of an interleukin‐2 fusion toxin (DAB486IL‐2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy

Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus

Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis

Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Interleukin-2 Receptor-Directed Therapies: Antibody-or Cytokine-Based Targeting Molecules

MRI assessment of knee osteoarthritis: Knee Osteoarthritis Scoring System (KOSS): inter-observer and intra-observer reproducibility of a compartment-based scoring system

AB1182 Cognitive Debrief of the English Version of the French Flare Assessment in Rheumatoid Arthritis (FLARE) Questionnaire in American English-Speaking RA Patients

FRI0203 Sustained Drug Free Remission in Early Ra Patients Treated To Target with Tocilizumab, Methotrexate or Their Combination

FRI0040 Protein Biomarkers Improves The Prediction of Clinical Response To Methotrexate Step-Up Strategy in Early RA Patients

Recombinant fusion toxins--a new class of targeted biologic therapeutics

OP0033 Rapid and Sustained Remission in Early Rheumatoid Arthritis (RA) Treated to Target with Tocilizumab, Methotrexate, or their Combination: The U-Act-Early Strategy Study

OP0250 Exploration of omeract preliminary rheumatoid arthritis (RA) flare domains in a longitudinal observational study

SAT0218 Validating Responsiveness and Discrimination of the Rheumatoid Arthritis Magnetic Resonance Imaging SCORE (RAMRIS) – A Meta-Analysis of Randomized Controlled Trials (RCTS) Identified in A Systematic Literature Review

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update

Interleukin‐2 diphtheria fusion protein (dab486il‐2) in refractory rheumatoid arthritis a double‐blind, placebo‐controlled trial with open‐label extension

Challenges and progress in adverse event ascertainment and reporting in clinical trials

Suchergebnisse filtern